Cost-effectiveness of first-v.second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. Aims: To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia. Method: Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice. Results: Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective. Conclusions: The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Cited by
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P. C., & Sculpher, M. (2015) · Health Technology Assessment · doi:10.3310/hta19140 · Cited by 853
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.033 · Cited by 276
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Metadata
- Authors
- Davies, L. M., Lewis, S., Jones, P. B., Barnes, T. R. E., Gaughran, F., Hayhurst, K., Markwick, A., & Lloyd, H.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2007-07
- Volume
- 191
- Issue
- 1
- Pages
- 14-22
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2120028475
- Cited by
- 107
- References
- 3
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of first-v.second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. https://app.cochat.ai/papers/10.1192/bjp.bp.106.028654
- The paper
- Davies, L. M., Lewis, S., Jones, P. B., Barnes, T. R. E., Gaughran, F., Hayhurst, K., Markwick, A., & Lloyd, H. (2007). Cost-effectiveness of first-v.second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry. https://doi.org/10.1192/bjp.bp.106.028654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.